Merck Clinical Trials Logo Merck Clinical Trials

Clinical Trial Finder

Merck Clinical Trial Finder

Trial Drug: Donepezil

The main purpose of this study is to assess the ability of a repeated high-frequency site-based computerized cognitive assessment to evaluate the potential treatment effects of donepezil (MK-0000) compared with placebo among participants with mild cognitive impairment (MCI) or mild Alzheimer’s Disease (AD). The primary study hypothesis is that the average percentage of correct responses on one card learning (OCL) task will be ≥2 percentage points in participants receiving donepezil compared with participants receiving placebo.

Cognition Platform Study in Participants at Risk for Alzheimer’s Disease

November 5, 2021

By clique_admin

The main purpose of this study is to assess the ability of a repeated high-frequency site-based computerized cognitive assessment to evaluate the potential treatment effects of donepezil (MK-0000) compared with placebo

Merck Clinical Trials Logo Merck Clinical Trials
  • Merck.com
  • Privacy Policy
  • Terms of Use
  • Policies & Perspectives
  • Cookie Preferences
  • Accessibility

Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

THIS WEBSITE IS INTENDED FOR A UNITED STATES AUDIENCE ONLY

Merck Essential Accessibility

Merck Essential Accessibility